Royal Bank of Canada’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,039
| Closed | -$7K | – | 7878 |
|
|
2023
Q2 | $7K | Buy |
1,039
+537
| +107% | +$3.56K | ﹤0.01% | 6595 |
|
|
2023
Q1 | $2K | Sell |
502
-14
| -3% | -$65 | ﹤0.01% | 6832 |
|
|
2022
Q4 | $2K | Sell |
516
-1,205
| -70% | -$5.51K | ﹤0.01% | 6972 |
|
|
2022
Q3 | $7K | Sell |
1,721
-172
| -9% | -$853 | ﹤0.01% | 6631 |
|
|
2022
Q2 | $10K | Sell |
1,893
-11
| -0.6% | -$72 | ﹤0.01% | 6406 |
|
|
2022
Q1 | $19K | Buy |
1,904
+1,198
| +170% | +$11.2K | ﹤0.01% | 6647 |
|
|
2021
Q4 | $7K | Buy |
706
+83
| +13% | +$1.24K | ﹤0.01% | 7158 |
|
|
2021
Q3 | $15K | Sell |
623
-39
| -6% | -$1.12K | ﹤0.01% | 6827 |
|
|
2021
Q2 | $26K | Sell |
662
-194
| -23% | -$8.45K | ﹤0.01% | 6432 |
|
|
2021
Q1 | $36K | Buy |
856
+148
| +21% | +$7.18K | ﹤0.01% | 6097 |
|
|
2020
Q4 | $30K | Buy |
708
+168
| +31% | +$9.19K | ﹤0.01% | 5889 |
|
|
2020
Q3 | $60K | Sell |
540
-787
| -59% | -$106K | ﹤0.01% | 5272 |
|
|
2020
Q2 | $143K | Buy |
1,327
+430
| +48% | +$38K | ﹤0.01% | 4644 |
|
|
2020
Q1 | $60K | Buy |
897
+48
| +6% | +$4.33K | ﹤0.01% | 5064 |
|
|
2019
Q4 | $71K | Buy |
+849
| New | +$57.3K | ﹤0.01% | 5268 |
|
Royal Bank of Canada's LMNL Position: Q3 2023 in Review
Royal Bank of Canada sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q3 2023, closing a stake of 1,039 shares — an estimated $7K sold.
Royal Bank of Canada first reported a position in LMNL in Q4 2019 and held it in 15 quarters. The position peaked at $143K in Q2 2020. 1 fund tracked by Wall St. Rank holds LMNL as of Q3 2023.
- Royal Bank of Canada reported no remaining Liminal BioSciences Inc. Common Shares position as of Q3 2023 after selling out during the quarter.
- Royal Bank of Canada sold 1,039 Liminal BioSciences Inc. Common Shares shares in Q3 2023, an estimated $7K.
- Royal Bank of Canada first reported a position in Liminal BioSciences Inc. Common Shares in Q4 2019 and held it in 15 quarters.
- Royal Bank of Canada's Liminal BioSciences Inc. Common Shares position peaked at $143K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q3 2023.
Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.